Welcome to LookChem.com Sign In | Join Free Post buying lead Chemical Tools
Home > Hot Product_List > Ezetimibe

Basic information

  • Name:
  • Ezetimibe

  • CAS No.:
  • 163222-33-1

  • Molecular Structure:
  • Formula:
  • C24H21F2NO3
  • Molecular Weight:
  • 409.43
  • Synonyms:
  • (-)-Sch 58235;Zetia (TN);Zetia;Ezetimibe 1-(4-flurophenyl)-(3R)-[3-(4-flurophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxyphenyl)-2-azetidinone;2-Azetidinone,1-(4-fluorophenyl)-3-[(3S)-3- (4-fluorophenyl)-3-hydroxypropyl]-4-(4- hydroxyphenyl)-,(3R,4S)-;Sch 58235;Vytorin;Ezedoc;(3R,4S)-1-(4-Fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone;
  • Density:
  • 1.334 g/cm3
  • Melting Point:
  • 164-166 °C
  • Boiling Point:
  • 654.9 °C at 760 mmHg
  • Flash Point:
  • 349.9 °C
  • Risk Codes:
  • 36/37/38
  • Safety Description:
  • 26-36 Details

Famous Chemical Enterprises

  • Livzon
  • Total
  • Shell
  • Dupont
  • Exxonmobil
  • Akzonobel
  • Basf
  • Bayer
  • BP

Please post your buying leads,so that our qualified suppliers will soon contact you!
*Required Fields

Chemistry

Name: Ezetimibe
Synonyms: 1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxy-propyl]-4-(4-hydroxyphenyl)-azetidin-2-one
CAS Registry Number: 163222-33-1
Molecular Formula: C24H21F2NO3
Molecular Weight: 409.43
Molecular Structure:
Mp: 164-166°C

Uses

Ezetimibe is an anti-hyperlipidemic medication which is used to lower Cholesterol levels. It acts by decreasing Cholesterol absorption in the intestine. It could be used alone when other Cholesterol-lowering medications are not tolerated, or when Cholesterol levels are unable to be controlled on statins alone, ezetimibe could be used together with statins

Safety Profile

Risk Statements: 36/37/38
R36/37/38:Irritating to eyes, respiratory system and skin.
Safety Statements: 26-36
S26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. 
S36:Wear suitable protective clothing.
Use cautiously in:
1)breastfeeding patients
2)children younger than age 10
3)pregnant patients not receiving HMG-CoA reductase inhibitors
4)renal or hepatic impairment
5)elderly patients.

Specification

Patient monitoring:
1)Monitor hepatic and lipid profiles
2)Assess for and report unexplained muscle pain.

Please post your buying leads
so that our qualified suppliers will soon contact you!

©2008 LookChem.com,License:ICP NO.:Zhejiang10014259

[Hangzhou]86-571-85317600,85317603,85317620